Osteoporosis Clinical Trial
Official title:
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Verified date | June 2021 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
Status | Completed |
Enrollment | 60 |
Est. completion date | August 25, 2020 |
Est. primary completion date | August 25, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - In-patient at Rehabilitation Institute of Chicago (RIC) or an outpatient who was recently discharged from RIC - Males and females - Age >/=18 years - Medically stable in the opinion of subject's physiatrist - SCI at within 120 days inclusive at time of screening - SCI with inability to ambulate independently - ASIA Impairment Scale (AIS) A, B, or C, at time of study entry - Capable of positioning to have DXA performed - Able to tolerate acetaminophen - No known endocrinopathies (diabetes type 1 or 2 can be included) - Normal TSH levels - Normal 25-OH vitamin D levels (>/= 20 ng/ml) at baseline (subjects may be repleted) - Normal calcium levels - Normal renal function (creatinine <2.0 mg/dl) - Well hydrated with adequate intake of liquids - Able to return for all follow-up visits - Capable of reading and understanding informed consent document - Males and females of childbearing potential must be willing and able to use double barrier method of contraception for 2 months after having received study drug Exclusion Criteria: - Have Paget's disease of the bone - Malignancy as a cause of acute SCI - Have unexplained high levels of alkaline phosphatase in blood - Any active gastrointestinal condition that results in malabsorption - Poor dental hygiene or requirement for invasive dental procedure within two months prior to enrollment - History of bone metastasis and skeletal malignancies - History of alcoholism or drug abuse within the 2 years prior to study screening - Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study - Elevated liver function tests >2x normal - Currently being prescribed anti-convulsants at a dose or frequency that is determined to interfere with bone metabolism as determined by the investigator - Currently being prescribed glucocorticoids, other than inhaled glucocorticoids - Current or recent use any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds within 60 days of screening. - Pregnant, planning to become pregnant, or lactating |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University Feinberg School of Medicine | Chicago | Illinois |
United States | Rehabilitation Institute of Chicago | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percent Change in Bone Mass Density (BMD) in the Hip | Percent change of bone mass density (BMD) in the total hip (as measured by DXA) | 0-12 months | |
Primary | Percent Change of Bone Mass Density (BMD) in the Femoral Neck | Percent change of bone mass density (BMD) in the femoral neck (as measured by DXA) | 0-12 months | |
Secondary | Percent Change in the Epiphyseal Integral Bone Mass Content (iBMC) of the Femur | Percent change in the epiphyseal integral bone mass content (iBMC) of the femur, as collected by CT. | 0-12 months | |
Secondary | Percent Change in the Metaphyseal Integral Bone Mass Content (iBMC) of the Femur | Percent change in the metaphyseal integral bone mass content (iBMC) of the femur, as collected by CT | 0-12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06287502 -
Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis
|
N/A | |
Completed |
NCT03822078 -
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women
|
Phase 1 | |
Recruiting |
NCT05845021 -
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
|
N/A | |
Completed |
NCT00092066 -
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
|
Phase 3 | |
Recruiting |
NCT04754711 -
Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition
|
N/A | |
Completed |
NCT04736693 -
Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
|
||
Not yet recruiting |
NCT06431867 -
Primary Care Management of Osteoporosis in Older Women
|
||
Completed |
NCT02922478 -
Role of Comorbidities in Chronic Heart Failure Study
|
||
Recruiting |
NCT02635022 -
Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
|
||
Recruiting |
NCT02616627 -
Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
|
||
Active, not recruiting |
NCT02617303 -
Prevention of Falls and Its Consequences in Elderly People
|
N/A | |
Completed |
NCT02566655 -
Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis
|
Phase 1 | |
Not yet recruiting |
NCT02223572 -
Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture
|
N/A | |
Completed |
NCT03420716 -
Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women
|
N/A | |
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Completed |
NCT02003716 -
DeFRA Questionnaire as an Anamnestic Form
|
N/A | |
Not yet recruiting |
NCT01854086 -
Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday
|
N/A | |
Unknown status |
NCT01913834 -
Nasally and sc Administered Teriparatide in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01401556 -
C-STOP Fracture Trial
|
N/A | |
Completed |
NCT01757340 -
Calorie Restriction With Leucine Supplementation
|
N/A |